Mumbai

Origo Cosmeceuticals Pvt Ltd is a leading company offering a unique range of cosmeceutical products in the Skin Whitening, Anti-ageing and Hair-care segment to its customers across India and the Middle-East. Our products are manufactured at our state-of-art facility in Bangkok, Thailand. We also offer tailored dermato-cosmetics products (contract manufacturing services) for many of the leading dermatologists/cosmetologists in India.

Post: Marketing Manager

Panacea Biotec is a leading research based Health Management Company, with an annual turnover of approx. Rs. 830 Crores. We are engaged in research, development, manufacture & marketing of Vaccines, Bio-Pharmaceuticals and Pharmaceuticals (Rx & OTC) of international quality and Health Services. All Panacea Biotec plants are accredited by international agencies and they follow current Good Manufacturing Practices, as per WHO guidelines.
We offer stimulating work environment & a career that spells growth. In tune with our plans, we require young, aggressive, dynamic, high performing and result oriented professional.

Post: Zonal Business Manager - Panacea Oncology Business Unit

Abbott India Limited is a subsidiary of Abbott Laboratories, USA, a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceutical, diagnostic, nutritional and hospital products. The company now employs approximately 70,000 people and markets its products in 130 countries worldwide.

Post: Associate Director - Government Affairs-1500000A43

Titan Laboratories Pvt. Ltd, Mahad (Maharashtra)
EU-GMP Manufacturers of Sustained & Modified Release Pellets, DC Granules, Taste Mask Granules, Tablets & Capsule.

Post: Junior Officer- ADL (M.Pharma - QA, Fresher)

Headquartered in Ireland, Perrigo Company plc is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products and receives royalties from Multiple Sclerosis drug Tysabri®. A leading US MNC Pharmaceutical- Perrigo

Post: Research Assistant ARD – Stability

The Institute of Chemical Technology (ICT) Mumbai was established as the Department of Chemical Technology on 1st October, 1933 by the University of Mumbai, through active support of industries and philanthropists. The Institute was most popularly known as UDCT, Mumbai. Research has been an integral part of ICT since its inception and it has created over 500 first generation entrepreneurs. The UDCT grew significantly in stature and was granted autonomy under UGC regulations by the University of Mumbai and further converted in to an Institute on 26th January, 2002. Under the World Bank TEQIP programme, the Maharashtra government granted it full autonomy in June 2004. Due to the recommendations of the Government of Maharashtra and University of Mumbai, the ICT was granted Deemed University Status by the MHRD on 12^th September, 2008, with all provisions of the UGC for funding and support as the state owned deemed university.

Applications are invited from suitable candidates for Senior Research Fellowship to work on the project entitled "Extraction of Volatile oil from Orange Peels, Separation of Limonene from it and its Industrial Applications" sponsored by Rajiv Gandhi Science and Technology Commission, Government Of Maharashtra, under the supervision of Prof. K.S.Laddha in the Pharmaceutical Division of this deparlment.

Post: Senior Research Fellow

{ DOWNLOAD AS PDF }

ABOUT AUTHORS:
Swati R. Dhande, Aruhana R. Patil*, Lilasrao J. Kadam
Bharati Vidyapeeth's College of Pharmacy,
Belapur, Navi Mumbai
*arpatil1991@gmail.com

ABSTRACT
Diabetes Mellitus (DM) is a metabolic endocrine disorder. It is one of the most rapidly growing diseases worldwide. Various pharmacotherapies have been practiced in the cure and management of DM. The existing conventional therapies aims at reducing hyperglycemia and achieving better glycemic control over the time, but fail to combat the other risk factors associated with the disease. The newer approaches are targeting to combat the risk factors and reduce the progression of disease. The newer approaches includes regenerational therapies, use of herbal and natural supplements, use of antioxidants and use combinations of conventional therapies with above mentioned therapies. Though these combinations have been found to be promising in the management of DM, the risk of pharmacological interactions cannot be overlooked. The present study was conducted to evaluate the pharmacokinetic interaction between DPP-IV inhibitor sitagliptin and a nutraceutical Z. officinale. STZ (Streptozotocin) and HFD (High Fat Diet) induced Type II DM rat model was used and the possible interaction was determined. The evaluation was done on validated HPTLC bioanalytical method. The present combination of sitagliptin and ginger did not affect the pharmacokinetic profile of sitagliptin.